Sangamo Therapeutics, Inc.
General ticker "SGMO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $148.8M (TTM average)
Sangamo Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -24.0%.
Estimated limits based on current volatility of 10.5%: low 0.15$, high 0.18$
Factors to consider:
- Total employees count: 183 (-54.8%) as of 2024
- Top business risk factors: Regulatory and compliance, Financing risks, Manufacturing risks, Supply chain disruptions, Cybersecurity threats
- Current price 41.4% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.30$, 0.81$]
- 2026-12-31 to 2027-12-31 estimated range: [0.32$, 0.82$]
Financial Metrics affecting the SGMO estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of -0.08 > -0.60
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term SGMO quotes
Long-term SGMO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $176.23MM | $57.80MM | $39.55MM |
| Operating Expenses | $450.24MM | $161.77MM | $160.79MM |
| Operating Income | $-274.00MM | $-103.97MM | $-121.24MM |
| Non-Operating Income | $11.10MM | $5.86MM | $-2.26MM |
| R&D Expense | $234.06MM | $111.52MM | $112.67MM |
| Income(Loss) | $-262.90MM | $-98.11MM | $-123.50MM |
| Taxes | $-5.07MM | $-0.17MM | $-0.57MM |
| Net Income(Loss)* | $-257.83MM | $-97.94MM | $-122.93MM |
| Stockholders Equity | $82.89MM | $22.77MM | $-14.27MM |
| Assets | $165.32MM | $101.64MM | $59.74MM |
| Operating Cash Flow | $-224.84MM | $-67.14MM | $-97.21MM |
| Capital expenditure | $21.16MM | $0.27MM | $0.10MM |
| Investing Cash Flow | $153.53MM | $37.52MM | $-0.10MM |
| Financing Cash Flow | $14.59MM | $28.38MM | $70.75MM |
| Earnings Per Share** | $-1.48 | $-0.49 | $-0.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.